Page last updated: 2024-08-21

pyrazines and Cancer of Ovary

pyrazines has been researched along with Cancer of Ovary in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.56)	18.7374
1990's	2 (3.13)	18.2507
2000's	19 (29.69)	29.6817
2010's	32 (50.00)	24.3611
2020's	10 (15.63)	2.80

Authors

Authors	Studies
Cheng, SC; Chowdhury, D; Curtis, J; D'Andrea, AD; da Costa, AABA; Färkkilä, A; Gulhan, D; Hendrickson, AEW; Kochupurakkal, B; Kohn, EC; Kolin, DL; Konstantinopoulos, PA; Lee, EK; Liu, JF; Matulonis, UA; Polak, M; Shapiro, GI; Stover, EH; Tayob, N	1
Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P	1
Jiang, H; Jiang, S; Li, X; Liang, C; Liu, L; Ruan, T; Song, J; Ye, H; Zhang, Y; Zhuo, C	1
D'Andrea, AD; Do, KT; Dunn, CE; Färkkilä, A; Kirschmeier, PT; Kochupurakkal, BS; Konstantinopoulos, PA; Lazaro, JB; Liu, JF; Matulonis, UA; Palakurthi, S; Parmar, K; Reavis, HD; Reznichenko, E; Sambel, LA; Shapiro, GI; Wang, ZC; Yang, C; Zou, L	1
Li, R; Liu, P; Liu, T; Luan, W; Mao, H; Shi, J; Wei, X; Yu, J	1
Barra, F; Costantini, S; Evangelisti, G; Ferrero, S; Gustavino, C; Moioli, M; Sala, P; Stigliani, S	1
Haynes, B; Huang, TT; Lee, JM; Murai, J; Nair, J; Pommier, Y; Steeg, PS	1
An, D; Cimino-Mathews, A; Lampert, EJ; Lee, JM; Lee, JS; Lee, MJ; Nair, J; Ruppin, E; Trepel, JB; Yuno, A	1
Ding, S; Xia, L; Zhang, H	1
Cho, HY; Kim, YB; No, JH; Park, WH	1
de Jonge, A; Do, KT; Giobbie-Hurder, A; Hu, J; Kelland, S; Manuszak, C; Powers, A; Severgnini, M; Shapiro, GI; Thrash, E	1
D'Andrea, AD; de Jonge, A; Do, KT; Gannon, C; Hedglin, J; Kelland, S; Kochupurakkal, B; Lazaro, JB; Parmar, K; Powers, A; Quinn, N; Shapiro, GI; Vuong, L	1
Annunziata, CM; Bagheri, MH; Botesteanu, DA; Ekwede, I; Harrell, MI; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Merino, MJ; Minasian, L; Nair, J; Steinberg, SM; Swisher, EM; Trepel, JB; Zimmer, A	1
Ferrandina, G; Scambia, G	1
Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G	1
Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C	1
Fernández, FM; Gaul, DA; Huang, D; Kim, J; Nan, H	1
Chao, A; Chen, HW; Chuang, WC; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH; Yen, TC	1
Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE	1
Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F	1
Dalton, HJ; Hu, W; Huang, J; Ivan, C; Jennings, NB; Kang, Y; Liu, J; Liu, T; Lu, C; Miyake, T; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Taylor, M; Wen, Y; Wu, SY; Zand, B	1
Annunziata, CM; Kohn, EC	1
Alsop, K; Au-Yeung, G; Bowtell, DD; D'Andrea, AD; Davis, S; Etemadmoghadam, D; George, J; Hahn, WC; Mitchell, G; Simpson, K; Weir, BA	1
Chang, TP; Gatla, HR; Manna, S; Poltoratsky, V; Sanacora, S; Singha, B; Vancura, A; Vancurova, I	1
Jiang, MY; Meng, Y; Shi, W; Song, HR; Wang, G	1
Draber, P; Graves, J; Montinaro, A; Newsom-Davis, T; Prieske, K; Prieske, S; Tuthill, MH; von Karstedt, S; Walczak, H; Zinngrebe, J	1
Amm, HM; Burke, MR; Dobbin, ZC; Jeong, DH; Katre, AA; Landen, CN; Steg, AD	1
Abbott, DH; Kropp, J; Ringelstetter, AK; Roti Roti, EC; Salih, SM	1
Chao, A; Chen, GC; Chuang, WC; Huang, WP; Kao, C; Lai, CH; Lin, CY; Tsai, CL; Wang, HS; Wang, TH	1
Garde-Granger, P; Lane, D; Laplante, C; Matte, I; Piché, A; Rancourt, C	1
Chen, G; Gong, C; Liu, Y; Sun, C; Weng, D; Yang, Z	1
Chernoff, J; Prudnikova, TY	1
Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L	1
Bazzaro, M; Bradner, J; Bristow, RE; Chan, KC; Lee, MK; Lin, Z; Mazitschek, R; Roden, RB; Santillan, A; Wang, MC	1
Brüning, A; Burger, P; Burges, A; Friese, K; Lenhard, M; Rahmeh, M; Vogel, M	1
Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Weng, DH; Xing, H	1
Alexiadis, M; Chu, S; Fuller, PJ	1
Elliott, GI; Farshchi-Heydari, S; Howell, SB; Jandial, DD; Larson, CA; Wrasidlo, WJ	1
Ahmed, M; Al-Dayel, F; Al-Kuraya, KS; Bavi, P; Hussain, AR; Jehan, Z; Munkarah, A; Uddin, S	1
Aghajanian, C; Blessing, JA; Darcy, KM; DeGeest, K; Mannel, RS; Reid, G; Riordan, W; Rotmensch, J; Rubin, SC; Schilder, RJ	1
Benedetti-Panici, P; Cognetti, F; Greggi, S; Mariani, G; Pasquini, L; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U	1
Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Wang, W; Weng, DH; Xing, H	1
Chen, T; Fang, Y; Hu, Y; Jiang, X; Ma, D; Ma, Q; Meng, L; Tian, Y; Wang, B; Wang, S; Wu, P; Xia, X; Xu, G; Zhang, Q; Zhou, J	1
Chen, WJ; He, JL; Li, WM; Liu, HT; Liu, HZ; Wang, YX; Yang, Z; Yin, J; Yu, C	1
Deavers, MT; Gershenson, DM; King, ER; Malpica, A; Mok, SC; Tsang, YT; Wong, KK; Zu, Z	1
Agadjanian, H; Guo, X; Karlan, BY; Kwon, S; Miller, C; Nassanian, H; Orsulic, S; Taylor-Harding, B; Walsh, CS	1
Amerik, AY; Issaenko, OA	1
Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A	1
Benedetti, V; Cincinelli, R; Corna, E; De Cesare, M; Gatti, L; Perego, P; Zaffaroni, N; Zunino, F	1
Chang, CL; Hsu, YT; Hung, CF; Wang, C; Wu, CC; Wu, TC; Yang, YC	1
Aghajanian, C	1
Chiao, PJ; Davis, JJ; Dong, F; Fang, B; Guo, W; Teraishi, F; Wu, S; Zhang, L; Zhu, H	1
Aghajanian, C; Dizon, DS; Dupont, J; Raizer, JJ; Sabbatini, P; Spriggs, DR	1
Bazzaro, M; Lee, MK; Roden, RB; Santillan, A; Shih, IeM; Stirling, WL; Zoso, A	1
Benedetti-Panici, P; Biffoni, M; Cognetti, F; Ferretti, G; Humphreys, R; Mariani, G; Pasquini, L; Peschle, C; Petronelli, A; Petrucci, E; Saulle, E; Scambia, G; Testa, U	1
Jacquemont, C; Taniguchi, T	1
Branch, CD; Chada, S; Gopalan, B; Ramesh, R; Scott, A; Shanker, M	1
Coleman, RL; Gershenson, DM; Johnston, TA; Landen, CN; Levenback, C; Milam, MR; Ramirez, PT	1
Lin, ZH	1
Chimirri, A; Fenech, G; Grasso, S; Monforte, P	1
Conrad, CA; Edwards, CL; Forman, A; Freedman, RS; Grothey, A; Grove, W; Hasenburg, A; Kavanagh, JJ; Kudelka, AP; Meyers, CA; Varma, D; Verschraegen, CF	1
Conrad, CA; Gelke, CK; Grove, W; Kudelka, AP; Meyers, CA; Pazdur, R	1
Adams, J; Elliott, P; Frankel, A; Kerbel, RS; Man, S	1
Masuda, H; Naito, M; Tamai, H; Tanaka, T; Tateishi, M	1

Reviews

4 review(s) available for pyrazines and Cancer of Ovary

Article	Year
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer. Bulletin du cancer, 2021, Volume: 108, Issue:9S1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines	2021
Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Synergism; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrazines; Pyrazoles	2020
Clinical update: novel targets in gynecologic malignancies. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 16 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cisplatin; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; NF-kappaB-Inducing Kinase; Ovarian Neoplasms; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines	2004
[Issues related to basic research on uterine and ovarian tumor pathology]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2007, Volume: 36, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Human papillomavirus 16; Humans; Ovarian Neoplasms; Papillomavirus Infections; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Trastuzumab; Tumor Suppressor Protein p53; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms	2007

Trials

12 trial(s) available for pyrazines and Cancer of Ovary

Article	Year
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nature communications, 2021, 09-22, Volume: 12, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Deoxycytidine; DNA Replication; Female; Gemcitabine; Humans; Isoxazoles; Mutation; Oncogenes; Ovarian Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Recombinational DNA Repair; Retinoblastoma Binding Proteins	2021
Clinical outcomes of prexasertib monotherapy in recurrent Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:2 Topics: Aged; Cystadenocarcinoma, Serous; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Pyrazines; Pyrazoles; Tumor Microenvironment	2020
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 09-01, Volume: 27, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles	2021
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology, 2018, Volume: 149, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult	2018
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden	2013
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome	2008
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology, 2009, Volume: 115, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Young Adult	2009
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2012
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazines	2005
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Proteasome Inhibitors; Pyrazines	2008
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Carbamates; Carcinoma; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dyspnea; Female; Humans; Hyponatremia; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Phlebitis; Pyrazines; Pyridines; Survival Rate; Treatment Outcome	1998
Neurotoxicity of CI-980, a novel mitotic inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Cognition; Cognition Disorders; Colorectal Neoplasms; Female; Humans; Male; Memory; Memory Disorders; Middle Aged; Neuropsychological Tests; Neurotoxins; Ovarian Neoplasms; Pyrazines; Pyridines	1997

Other Studies

48 other study(ies) available for pyrazines and Cancer of Ovary

Article	Year
OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway. Medical oncology (Northwood, London, England), 2022, Jan-04, Volume: 39, Issue:2 Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance; Female; Imidazoles; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Signal Transduction	2022
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 10-15, Volume: 25, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Neoplasm Grading; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Recombinational DNA Repair; Xenograft Model Antitumor Assays	2019
ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo. Journal of translational medicine, 2019, 12-26, Volume: 17, Issue:1 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Down-Regulation; Endoplasmic Reticulum Stress; Endoribonucleases; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imidazoles; MAP Kinase Signaling System; Middle Aged; Naphthalenes; Neoplasm Grading; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Receptor Tyrosine Kinase-like Orphan Receptors; Transcription Factor CHOP; Tumor Stem Cell Assay	2019
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. Oncogene, 2020, Volume: 39, Issue:33 Topics: BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Pyrazines; Pyrazoles	2020
Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211. Bioscience reports, 2021, 01-29, Volume: 41, Issue:1 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Pyrazines	2021
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells. Cancer research and treatment, 2021, Volume: 53, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Checkpoint Kinase 1; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Rad51 Recombinase	2021
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer immunology, immunotherapy : CII, 2021, Volume: 70, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Pyrazines; Pyrazoles	2021
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet. Oncology, 2018, Volume: 19, Issue:2 Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; United States; Young Adult	2018
A turning point in the fight against ovarian cancer? The Lancet. Oncology, 2018, Volume: 19, Issue:2 Topics: Cell Cycle Checkpoints; Checkpoint Kinase 1; Female; Humans; Ovarian Neoplasms; Pyrazines; Pyrazoles	2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer discovery, 2018, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles	2018
Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model. Journal of proteome research, 2019, 08-02, Volume: 18, Issue:8 Topics: Animals; Bilirubin; Biomarkers, Tumor; Chromatography, Liquid; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Humans; Metabolomics; Mice; Mice, Knockout; Neoplasm Staging; Oligopeptides; Ovarian Neoplasms; Phospholipids; Pyrazines; Sphingomyelins; Sterols; Tandem Mass Spectrometry; Uridine	2019
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells. Cell death & disease, 2013, Feb-28, Volume: 4 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cisplatin; DNA-Binding Proteins; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Janus Kinases; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Phosphorylation; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Transcription Factors; Transplantation, Heterologous	2013
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer research, 2013, Jun-15, Volume: 73, Issue:12 Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan	2013
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Mice; Mice, Nude; Odds Ratio; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1	2013
Novel facts about FAK: new connections to drug resistance? Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Pyrazines; Sulfonamides; Y-Box-Binding Protein 1	2013
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proceedings of the National Academy of Sciences of the United States of America, 2013, Nov-26, Volume: 110, Issue:48 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; BRCA1 Protein; Cyclin E; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Microarray Analysis; Oncogene Proteins; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering	2013
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. The Journal of biological chemistry, 2014, Jan-31, Volume: 289, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Chemokine CCL2; Chemokine CXCL5; Early Growth Response Protein 1; Female; Gene Expression Regulation, Leukemic; Humans; I-kappa B Kinase; Interleukin-8; Multiple Myeloma; Ovarian Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription Factor RelA	2014
Cellular mechanisms of a new pyrazinone compound that induces apoptosis in SKOV-3 cells. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:2 Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Female; Flow Cytometry; Hemolysis; Humans; Ovarian Neoplasms; Pyrazines; Rabbits; Tumor Cells, Cultured	2014
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene, 2015, Apr-16, Volume: 34, Issue:16 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Survival; Drug Synergism; Female; Hepatocytes; Humans; Ovarian Neoplasms; Protein Binding; Pyrazines; Receptors, IgG; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins	2015
Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget, 2014, Aug-30, Volume: 5, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Boronic Acids; Bortezomib; Bridged-Ring Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Hedgehog Proteins; Humans; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; Pyridines; Signal Transduction; Taxoids	2014
Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice. PloS one, 2014, Volume: 9, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Birth Weight; Boronic Acids; Bortezomib; DNA Damage; Doxorubicin; Female; Fertility; Humans; Litter Size; Mice; Ovarian Follicle; Ovarian Neoplasms; Ovary; Primary Ovarian Insufficiency; Pyrazines	2014
Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell death & disease, 2014, Nov-06, Volume: 5 Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cisplatin; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; MAP Kinase Kinase 4; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phagosomes; Phosphorylation; Proteasome Inhibitors; Pyrazines; Signal Transduction	2014
Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms. International journal of cancer, 2015, Jul-15, Volume: 137, Issue:2 Topics: Ascites; Cell Movement; Cells, Cultured; Cytokines; Enzyme Activation; Epithelial Cells; ErbB Receptors; Female; Hepatocyte Growth Factor; Humans; Immunoblotting; Inflammation Mediators; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; Peritoneal Cavity; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazoles	2015
[Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:11 Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cisplatin; DNA Repair; Female; Humans; Ovarian Neoplasms; Pyrazines; RNA, Small Interfering; Sulfones; Transfection	2014
The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases, 2017, 10-02, Volume: 8, Issue:4 Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Chromosomes, Human, Pair 11; Drug Synergism; Female; Humans; Ovarian Neoplasms; p21-Activated Kinases; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Signal Transduction	2017
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22 Topics: Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Movement; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Immunohistochemistry; Immunoprecipitation; Ovarian Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tissue Array Analysis; Ubiquitin	2008
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investigational new drugs, 2009, Volume: 27, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; Pyrazines; Stress, Physiological; Time Factors; Up-Regulation	2009
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]. Zhonghua fu chan ke za zhi, 2008, Volume: 43, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction	2008
Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors. Reproductive sciences (Thousand Oaks, Calif.), 2009, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression; Granulosa Cell Tumor; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; X-Linked Inhibitor of Apoptosis Protein	2009
Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper Transporter 1; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Peritoneal Neoplasms; Proteasome Endopeptidase Complex; Pyrazines	2009
Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Laboratory investigation; a journal of technical methods and pathology, 2009, Volume: 89, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Enzyme Activation; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mitochondria; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Transplantation, Heterologous; Up-Regulation	2009
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. International journal of oncology, 2010, Volume: 36, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Ovarian Neoplasms; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand	2010
[Proteasome inhibitors sensitize ovarian cancer cells to cisplatin]. Zhonghua fu chan ke za zhi, 2010, Volume: 45, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Protease Inhibitors; Pyrazines	2010
Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341. Cancer investigation, 2011, Volume: 29, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; Time Factors	2011
Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. Oncology reports, 2011, Volume: 26, Issue:3 Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Coculture Techniques; Female; Genes, Reporter; Humans; Interleukin-8; Luciferases; Mitogen-Activated Protein Kinases; Monocytes; Ovarian Neoplasms; Phosphorylation; Pyrazines; Signal Transduction; Transcription Factor AP-1; Transcription, Genetic	2011
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecologic oncology, 2011, Volume: 123, Issue:1 Topics: Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Up-Regulation	2011
Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. British journal of cancer, 2012, Jan-17, Volume: 106, Issue:2 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Synergism; Female; Flow Cytometry; Humans; Indoles; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Pyrazines; Real-Time Polymerase Chain Reaction; Xenograft Model Antitumor Assays	2012
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell cycle (Georgetown, Tex.), 2012, 05-01, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins	2012
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Journal of inorganic biochemistry, 2012, Volume: 113 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzothiazoles; Boronic Acids; Bortezomib; Carcinoma; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasm Proteins; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Toluene; Tumor Suppressor Protein p53	2012
Immune mechanism of the antitumor effects generated by bortezomib. Journal of immunology (Baltimore, Md. : 1950), 2012, Sep-15, Volume: 189, Issue:6 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chaperonin 60; Female; HSP90 Heat-Shock Proteins; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Mitochondrial Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Pyrazines; Up-Regulation	2012
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene, 2005, Jul-21, Volume: 24, Issue:31 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Female; Humans; Kidney; Membrane Proteins; Mitochondrial Proteins; NF-kappa B; Ovarian Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2005
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer research, 2006, Apr-01, Volume: 66, Issue:7 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Division; Cell Line, Tumor; Female; G2 Phase; Humans; Leupeptins; Mice; Mice, Nude; Oligopeptides; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Xenograft Model Antitumor Assays	2006
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Humans; Leupeptins; Membrane Proteins; Mitochondria; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand	2007
Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer research, 2007, Aug-01, Volume: 67, Issue:15 Topics: Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Cycle Proteins; Cells, Cultured; DNA Damage; DNA Repair; DNA-Binding Proteins; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Female; Flow Cytometry; Gamma Rays; HeLa Cells; Humans; Leupeptins; Microscopy, Fluorescence; Nuclear Proteins; Ovarian Neoplasms; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Rad51 Recombinase; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin	2007
MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity. Cancer gene therapy, 2008, Volume: 15, Issue:1 Topics: Adenoviridae; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Female; Genetic Therapy; Humans; Interleukins; Lung Neoplasms; Lysosomes; Ovarian Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Proteins; Ubiquitin; Ubiquitination	2008
[Compounds with presumable antitumor activity. III. 1-Substituted N,N'-di-2-pyrimidinyl (or pyrazinyl)methylenediamine]. Il Farmaco; edizione scientifica, 1984, Volume: 39, Issue:9 Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Diamines; Female; Leukemia L1210; Leukemia P388; Mammary Neoplasms, Experimental; Melanoma; Mice; Ovarian Neoplasms; Pyrazines; Pyrimidines; Rats	1984
Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:9 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma; Caspase Inhibitors; Caspases; Cell Adhesion; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Female; Humans; Male; Ovarian Neoplasms; Phosphorylation; Prostatic Neoplasms; Protease Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2000
Detection and cytotoxicity of cisplatin-induced superoxide anion in monolayer cultures of a human ovarian cancer cell line. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:2 Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Female; Humans; Imidazoles; Luminescent Measurements; Ovarian Neoplasms; Pyrazines; Superoxide Dismutase; Superoxides; Tumor Cells, Cultured	2001